Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P06889 (Mol)
 630,302 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of an associated treatment with Ciprofibrate and Simvastatin upon plasma lipid parameters, liver Mixed Function Oxidases enzymes and peroxisomal markers have been studied in male Wistar rats. The association was efficient upon triglycerides, but not upon cholesterol. The inducive and proliferative effects commonly exerted by Ciprofibrate (5 mg/kg/day) were not significantly modified by the simultaneous treatment with Simvastatin (10 mg/kg/day). The increase of the seric alanine amino transferase activity was however much more pronounced after the associated treatment than after single administration of Ciprofibrate or Simvastatin.
Cell Mol Biol 1991
PMID:Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat. 180 86

The impact of lowering the ovarian L(iver)-type lipase activity on cholesterol homeostasis in the ovaries was studied in superovulated rats. L-type lipase activity increased rapidly after injection with chorionic gonadotrophin (HCG) (day 0), its activity remained high between days 3 and 8. During this period plasma progesterone and 20 alpha-hydroxyprogesterone were raised. The ovarian content of unesterified cholesterol remained constant during this period while cholesterol esters increased. Lowering of the L-type lipase activity by in vivo treatment with anti-liver lipase (ALLA) during 4-5 h did not affect plasma hormones or ovarian cholesterol contents. However, de novo cholesterol synthesis in the ovaries was significantly increased by about 40%. After pretreatment of the rats with aminogluthetimide, ALLA administration led to a 250% increase in de novo cholesterol synthesis in the unesterified cholesterol fraction, but was without effect on plasma hormones and on the ovarian cholesterol content. Administration of the cholesterol synthesis inhibitor Simvastatin led to a 25% lowering in ovarian cholesterol synthesis without effect on plasma hormones or ovarian cholesterol content. Additional administration of ALLA affected only the plasma progesterone (-30%). These results indicate that L-type lipase is involved in ovarian cholesterol homeostasis.
Mol Cell Endocrinol 1988 May
PMID:L-type lipase activity in ovaries of superovulated rats. Relation to cholesterol homeostasis. 339 58

Activity of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the key enzyme in the biosynthesis of steroids and polyisoprenoids in mammalian cells, has been detected in both the bloodstream form and the culture-adapted procyclic form of Trypanosoma brucei (3.7 +/- 0.6 and 12.7 +/- 1.8 pmol mevalonate produced min-1 (mg cell protein)-1, respectively). The enzyme activity is enriched 6-fold in microsomal fractions. Several competitive inhibitors of mammalian HMG-CoA reductase, including synvinolin (simvastatin), inhibit the multiplication of both forms of trypanosome in vitro (IC50, approx. 25-50 microM after 2-3 days). This growth inhibition is potentiated by agents interfering with the exogenous supply of cholesterol, such as antibodies blocking the low-density lipoprotein (LDL) receptor, or 5 microM chloroquine. Conversely, growth inhibition by synvinolin can be largely reverted either by 300 nM LDL or by products of the mevalonate pathway, such as 20 mM mevalonate and in procyclics by 100 microM squalene or cholesterol. In procyclics, low concentrations of synvinolin selectively inhibit the incorporation of [14C]acetate into sterols, but not into fatty acids. These results argue for a critical role in trypanosomes of a mevalonate pathway, that is involved in the biosynthesis of sterol and probably of other metabolites. The HMG-CoA reductase activity is decreased 2-fold in procyclics incubated with 4 mM mevalonate and increased 2-fold in the presence of 2.5 microM synvinolin. Synvinolin also upregulates LDL binding up to 4-fold. These data suggest that HMG-CoA reductase and LDL receptor expression are regulated in T. brucei as in mammalian cells, to ensure sterol homeostasis.
Mol Biochem Parasitol 1995 Jan
PMID:Activity, pharmacological inhibition and biological regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in Trypanosoma brucei. 772 86

One of the major side-effects of the use of HMG CoA reductase inhibitors for the treatment of hypercholesterolemia is the development of myositis and, in some patients undergoing concomitant immunosuppressive treatment, the development of rhabdomyolysis. Experiments outlined in these studies demonstrate that inhibitors of HMG-CoA reductase activity which differ primary in the substitution of a methyl group for a hydroxyl group have differential effects on both cholesterol levels and cell viability in a striated muscle cell model, the mouse C2-C12 myoblast. Thus, concentrations as high as 200 microM of pravastatin had little effect on total cholesterol level while 25 microM of lovastatin decreased cellular cholesterol by over 90%. Simvastatin and lovastatin decreased viability of C2-C12 myoblasts by nearly 50% at concentrations as low as 1 and 5 microM, respectively, and decreased viability by almost 90% at 10 and 15 microM respectively. However, 300 microM of pravastatin decreased cell viability by less than 50%. The order of potency for the effects on cell viability wassimvastatin>lovastatin>>>pravastatin. The possible relationship between effects on cell viability and the development of myositis is discussed.
J Mol Cell Cardiol 1995 Oct
PMID:Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. 857 54

The growth of the culture-adapted procyclic forms of Trypanosoma brucei (procyclics) is accelerated by supplementation of the medium with low-density lipoprotein (LDL) particles. This effect can be attributed to receptor-mediated endocytosis of LDL, followed by utilization of lipids carried by the lipoproteins. Indeed, procyclics that normally contain ergosterol synthesized de novo, also incorporate exogenous cholesterol in their membranes. In turn, import of exogenous lipids down-regulates the isoprenoid biosynthetic machinery as measured by a approx. 3-fold decrease of [14C]acetate incorporation into sterols and a approx. 2-fold decrease of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity, compared with cells grown in lipoprotein-depleted medium. Synvinolin, a specific inhibitor of HMG-CoA reductase that slows down the procyclic growth in vitro and decreases [14C]acetate incorporation into sterols, produces striking morphological modifications, including an arrest at cytokinesis and an extensive swelling of the kinetoplast-mitochondrion system. These cytotoxic effects are amplified in the absence of lipoprotein supply. In conclusion, procyclics may acquire sterols from both exogenous and endogenous sources. To a large extent, these two pathways compensate each other, illustrating adaptation of the parasites to survive in extremely different environments.
Mol Biochem Parasitol 1995 Jul
PMID:Exogenous and endogenous sources of sterols in the culture-adapted procyclic trypomastigotes of Trypanosoma brucei. 857 25

The peroxisome proliferator ciprofibrate induces hypergastrinemia without inhibiting acid secretion. The present study was carried out to assess the effect of ciprofibrate on serum gastrin and gastrin (G) cells in different strains of rats and to compare the effect of ciprofibrate with other lipid-reducing agents (lovastatin and simvastatin) which have a different mechanism of action. Serum gastrin was determined by a radioimmunoassay method, G cell density by histomorphometry after immunostaining for G cells, and gastrin, somatostatin and histidine decarboxylase (HDC) mRNA abundance by Northern blot analysis. Ciprofibrate (100 mg/kg/day for three weeks) induced a marked hypergastrinemia (P < 0.01) in male and female Fischer rats as well as in female Wistar rats. Simvastatin and lovastatin did not affect serum gastrin. Antral G cell density increased significantly in female Wistar rats (P < 0.05) and non-significantly in the other rats after ciprofibrate. Both gastrin and somatostatin mRNA abundance in antral mucosa increased markedly and significantly (P < 0.01) after ciprofibrate treatment. The present study shows that the peroxisome proliferator ciprofibrate induces hypergastrinemia secondary to an increased storage and synthesis of antral gastrin. Since somatostatin mRNA abundance also increased, the present study suggests that ciprofibrate and possibly other peroxisome proliferators in sufficient concentrations have a stimulatory effect on endocrine cells.
J Mol Endocrinol 1998 Feb
PMID:The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particularly the gastrin cell. 951 87

This paper shows for the first time the higher oxidizability of low-density lipoprotein (LDL) in plasma from adrenoleukodystrophy (ALD) patients compared to that of control subjects. LDL oxidation susceptibility was assessed by conjugate diene formation, hydroperoxide and lipoperoxide formation, and electrophoretic mobility. Simvastatin therapy, an HMG-CoA reductase inhibitor, seems to be a protective pharmacological agent against the higher oxidizability of LDL in plasma from ALD patients.
Mol Genet Metab 2000 Dec
PMID:Susceptibility to oxidation of plasma low-density lipoprotein in X-linked adrenoleukodystrophy: effects of simvastatin treatment. 1113 59

Connective tissue growth factor (CTGF), a potent profibrotic mediator, acts downstream and in concert with transforming growth factor (TGF)-beta to drive fibrogenesis. Significant upregulation of CTGF has been reported in fibrogenic diseases, including idiopathic pulmonary fibrosis (IPF), and is partly responsible for associated excessive fibroblast proliferation and extracellular matrix deposition, but no effective therapy exists for averting such fibrogeneic events. Simvastatin has reported putative antifibrotic actions in renal fibroblasts; this study explores such actions on human IPF-derived and normal lung fibroblasts and examines associated driving mechanisms. Simvastatin reduces basal CTGF gene and protein expression in all fibroblast lines, overriding TGF-beta induction through inhibition of the cholesterol synthesis pathway. Signaling pathways driving simvastatin's effects on CTGF/TGF-beta interaction were evaluated using transient reporter transfection of a CTGF promoter construct. Inhibition of CTGF promoter activity by simvastatin was most marked at 10 muM concentration, reducing activity by 76.2 and 51.8% over TGF-beta-stimulated cultures in IPF and normal fibroblasts, respectively. We also show that geranylgeranylpyrophosphate (GGPP), but not farnesylpyrophosphate, induces CTGF promoter activity following simvastatin inhibition by 55.3 and 31.1% over GGPP-negative cultures in IMR90 and IPF-derived fibroblasts, respectively, implicating small GTPase Rho involvement rather than Ras in these effects. Indeed, the specific Rho inhibitor C3 exotoxin significantly (P < 0.05) suppressed TGF-beta-induced CTGF promoter activity in transfected lung fibroblasts, a finding further supported by transfection of dominant-negative and constitutively active RhoA constructs, thus demonstrating that simvastatin through a Rho signaling mechanism in lung fibroblasts can modulate CTGF expression and interaction with TGF-beta.
Am J Physiol Lung Cell Mol Physiol 2004 Dec
PMID:Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism. 1529 57

Statins have cardioprotective roles. We explored the cardiac angiogenic effects of simvastatin in combination with transient overexpression of vascular endothelial growth factor (VEGF). Compared with normal mice, 1-year-old ApoE(-/-) mice fed on a high-fat diet (HFD) had about 30% less myocardial capillary (P < 0.001) and arteriolar (P < 0.03) densities, associated with decreased VEGF (55%), VEGFR-1 (56%) and VEGFR-2 (78%) mRNA expressions and myocardial endothelial nitric oxide synthase (eNOS) production (58%). By contrast, angiopoietin-1 and angiopoietin-2 mRNA expressions were increased (500% P < 0.02, and 400% P < 0.01, respectively) in the ApoE(-/-) hearts. No change was observed in Tie-2 gene expression. Phosphorylation of antiapoptotic Akt was lower and proapoptotic p38 mitogen-activated protein kinase (MAPK) was higher in the ApoE(-/-) mice compared with controls. Intramyocardial VEGF gene transfer increased capillary and arteriolar densities in the ApoE(-/-) mice, and simvastatin treatment further enhanced capillary density (P < 0.03) to a level similar to that of normal mice. Simvastatin did not change the lipid profile but blocked p38 MAPK phosphorylation in the ApoE(-/-) myocardium. Concurrent with these changes, there were increased levels of expression of mVEGF (P < 0.04) and VEGFR-2 (P < 0.03) mRNAs and increased production of eNOS (P < 0.05) in the ApoE(-/-) mice, while no changes were detected in the angiopoietin system. Thus, increased myocardial angiogenesis in the ApoE(-/-) mice following transient overexpression of VEGF is further increased by additional simvastatin treatment. These effects occurred concurrently with simvastatin-induced stimulation of the VEGF system, increased eNOS production and reduction in p38 MAPK phosphorylation.
J Mol Cell Cardiol 2004 Dec
PMID:Simvastatin enhances myocardial angiogenesis induced by vascular endothelial growth factor gene transfer. 1557 54

Therapies to limit the life-threatening vascular leak observed in patients with acute lung injury (ALI) are currently lacking. We explored the effect of simvastatin, a 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor that mediates endothelial cell barrier protection in vitro, in a murine inflammatory model of ALI. C57BL/6J mice were treated with simvastatin (5 or 20 mg/kg body wt via intraperitoneal injection) 24 h before and again concomitantly with intratracheally administered LPS (2 microg/g body wt). Inflammatory indexes [bronchoalveolar lavage (BAL) myeloperoxidase activity and total neutrophil counts assessed at 24 h with histological confirmation] were markedly increased after LPS alone but significantly reduced in mice that also received simvastatin (20 mg/kg; approximately 35-60% reduction). Simvastatin also decreased BAL albumin (approximately 50% reduction) and Evans blue albumin dye extravasation into lung tissue (100%) consistent with barrier protection. Finally, the sustained nature of simvastatin-mediated lung protection was assessed by analysis of simvastatin-induced gene expression (Affymetrix platform). LPS-mediated lung gene expression was significantly modulated by simvastatin within a number of gene ontologies (e.g., inflammation and immune response, NF-kappaB regulation) and with respect to individual genes implicated in the development or severity of ALI (e.g., IL-6, Toll-like receptor 4). Together, these findings confirm significant protection by simvastatin on LPS-induced lung vascular leak and inflammation and implicate a potential role for statins in the management of ALI.
Am J Physiol Lung Cell Mol Physiol 2005 Jun
PMID:Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. 1566 42


1 2 3 4 5 6 7 8 9 10 Next >>